Repligen Corporation Share Price

Equities

RGEN

US7599161095

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 01:30:00 27/04/2024 am IST 5-day change 1st Jan Change
166.6 USD +0.56% Intraday chart for Repligen Corporation +6.01% -7.35%
Sales 2024 * 638M 53.18B Sales 2025 * 739M 61.63B Capitalization 9.3B 776B
Net income 2024 * 43M 3.59B Net income 2025 * 88M 7.34B EV / Sales 2024 * 14.2 x
Net cash position 2024 * 276M 23.03B Net cash position 2025 * 386M 32.21B EV / Sales 2025 * 12.1 x
P/E ratio 2024 *
314 x
P/E ratio 2025 *
112 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.41%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.56%
1 week+6.01%
Current month-9.43%
1 month-9.39%
3 months-13.87%
6 months+35.98%
Current year-7.35%
More quotes
1 week
154.87
Extreme 154.87
174.30
1 month
152.19
Extreme 152.19
187.25
Current year
152.19
Extreme 152.19
211.13
1 year
110.45
Extreme 110.45
211.13
3 years
110.45
Extreme 110.45
327.32
5 years
63.02
Extreme 63.02
327.32
10 years
15.30
Extreme 15.3
327.32
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 01/14/01
President 54 02/23/02
Director of Finance/CFO 50 25/23/25
Members of the board TitleAgeSince
Chairman 72 01/05/01
Director/Board Member 58 12/14/12
Director/Board Member 64 06/23/06
More insiders
Date Price Change Volume
26/24/26 166.6 +0.56% 341,269
25/24/25 165.7 -1.31% 238,746
24/24/24 167.9 -2.00% 545,959
23/24/23 171.3 +8.76% 928,614
22/24/22 157.5 +0.22% 294,448

Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST

More quotes
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. The Company's bioprocessing business consists of four main franchises: filtration (including fluid management); chromatography; process analytics, and proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. The Company’s chromatography franchise includes a number of products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. The Company’s TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
166.6 USD
Average target price
210.9 USD
Spread / Average Target
+26.59%
Consensus